Kaya Holdings launches Fifth Dimension Therapeutics to enter psychedelic treatment market

Kaya Holdings, Inc.

Fifth Dimension Therapeutics will target PTSD, addiction, eating disorders, and treatment-resistant mental health conditions.
Employee Bryan Arnold enrolled in Oregon Psilocybin Facilitator training; expected to complete and apply for license in April 2023.
Attorney Glenn E.J. Murphy joins FDT board to assist with pharma partnerships, IP, and funding opportunities.
Company cites $2.8B U.S. psychedelics market in 2021, forecast to reach $8.9B by 2029.
KAYS shifts cannabis focus to Europe while launching psychedelic 'mind care' operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.